Emergency contraception
Drug Safety Update
February 2021: Ulipristal acetate 5mg (Esmya): further restrictions due to risk of serious liver injury
March 2020: Esyma (ulipristal acetate) suspension of the licence due to risk of serious liver injury
August 2018: Esmya (ulipristal acetate) and risk of serious liver injury: new restrictions to use and requirements for liver function monitoring before, during, and after treatment
March 2018: Esmya (ulipristal acetate) for uterine fibroids: do not initiate or re-start treatment; monitor liver function in current and recent users
September 2016: Levonorgestrel-containing emergency hormonal contraception: advice on interactions with hepatic enzyme inducers and contraceptive efficacy
August 2014: Levonorgestrel and ulipristal remain suitable emergency contraceptives for all women
See above Drug Safety Update link: the licence for ulipristal (Esyma) has been suspended, current treatment should be stopped and no new patients commenced on this treatment
Ulipristal (EllaOne) is still licensed for emergency contraception
| Pack | Price |
|---|---|
| 1 tablet | £14.05 |
licence has been suspended due to safety concerns please see Drug Safety Update link above. Current treatment should be stopped and no patients started on this treatment
| Pack | Price |
|---|---|
| 28 tablet (2 x 14 tablets) | £114.13 |